Top

Published in:

01-06-2020 | Acute Myeloid Leukemia | Original Article

Metabolomics analysis identifies lysine and taurine as candidate prognostic biomarkers for AML-M2 patients

Authors: Xuan Zhou, Meihong Zheng, Qien Wang, Jiye Aa, Bei Cao, Juan Li

Published in: International Journal of Hematology | Issue 6/2020

Abstract

There is an ongoing search for potential biomarkers for acute myeloid leukemia (AML) patients using metabolic analysis. However, only few studies to date have focused on bone marrow samples or a specific subtype of AML. In the present study, we used gas chromatography time-of-flight mass spectrometry of plasma and bone marrow supernatants to compare the metabolic characteristics of patients with AML with maturation (AML-M2). This approach identified significantly altered metabolites. We next performed pathway analysis and determined relative mRNA expression by qRT-PCR. Our results show that lysine, methionine and serine were significantly decreased in AML-M2 patients compared with healthy control. Moreover, plasma abundance of lysine was negatively associated with patients’ risk stratification. Taurine had higher plasma abundance in AML-M2 patients and plasma level of taurine was positively related with AML-M2 risk status, while the expression level of taurine transporter showed a negative correlation. Receiver operating characteristic curve analysis showed these four metabolites had high diagnostic value with lysine showing the highest sensitivity and specificity. These results suggest that plasma abundances of lysine and taurine may serve as potential metabolic biomarkers for the prognosis of patients with AML-M2.

Available only for authorised users

Foran JM. New prognostic markers in acute myeloid leukemia: perspective from the clinic. Hematol Am Soc Hematol Educ Program. 2010;2010:47–55. https://doi.org/10.1182/asheducation-2010.1.47.CrossRef

Prada-Arismendy J, Arroyave JC, Rothlisberger S. Molecular biomarkers in acute myeloid leukemia. Blood Rev. 2017;31(1):63–766. https://doi.org/10.1016/j.blre.2016.08.005.CrossRefPubMed

Gallipoli P, Giotopoulos G, Tzelepis K, Costa ASH, Vohra S, Medina-Perez P, et al. Glutaminolysis is a metabolic dependency in FLT3(ITD) acute myeloid leukemia unmasked by FLT3 tyrosine kinase inhibition. Blood. 2018;131(15):1639–53. https://doi.org/10.1182/blood-2017-12-820035.CrossRefPubMed

Liu X, Locasale JW. Metabolomics: a primer. Trends Biochem Sci. 2017;42(4):274–84. https://doi.org/10.1016/j.tibs.2017.01.004.CrossRefPubMedPubMedCentral

Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell. 2011;144(5):646–74. https://doi.org/10.1016/j.cell.2011.02.013.CrossRefPubMed

Pasikanti KK, Esuvaranathan K, Hong Y, Ho PC, Mahendran R, Raman Nee Mani L, et al. Urinary metabotyping of bladder cancer using two-dimensional gas chromatography time-of-flight mass spectrometry. J Proteome Res. 2013;12(9):3865–73. https://doi.org/10.1021/pr4000448.CrossRefPubMed

Mondal S, Roy D, Camacho-Pereira J, Khurana A, Chini E, Yang L, et al. HSulf-1 deficiency dictates a metabolic reprograming of glycolysis and TCA cycle in ovarian cancer. Oncotarget. 2015;6(32):33705–19. https://doi.org/10.18632/oncotarget.5605.CrossRefPubMedPubMedCentral

Bro R, Kamstrup-Nielsen MH, Engelsen SB, Savorani F, Rasmussen MA, Hansen L, et al. Forecasting individual breast cancer risk using plasma metabolomics and biocontours. Metabolomics. 2015;11(5):1376–80. https://doi.org/10.1007/s11306-015-0793-8.CrossRefPubMedPubMedCentral

Kumar N, Shahjaman M, Mollah MNH, Islam SMS, Hoque MA. Serum and plasma metabolomic biomarkers for lung cancer. Bioinformation. 2017;13(6):202–8. https://doi.org/10.6026/97320630013202.CrossRefPubMedPubMedCentral

10.

Yin P, Xu G. Metabolomics toward biomarker discovery. Methods Mol Biol. 2017;1619:467–75. https://doi.org/10.1007/978-1-4939-7057-5_32.CrossRefPubMed

11.

Du H, Wang L, Liu B, Wang J, Su H, Zhang T, et al. Analysis of the metabolic characteristics of serum samples in patients with multiple myeloma. Front Pharmacol. 2018;9:884. https://doi.org/10.3389/fphar.2018.00884.CrossRefPubMedPubMedCentral

12.

Musharraf SG, Siddiqui AJ, Shamsi T, Naz A. SERUM metabolomics of acute lymphoblastic leukaemia and acute myeloid leukaemia for probing biomarker molecules. Hematol Oncol. 2017;35(4):769–77. https://doi.org/10.1002/hon.2313.CrossRefPubMed

13.

Warburg O. On the origin of cancer cells. Science. 1956;123(3191):309–14.CrossRefPubMed

14.

Herst PM, Howman RA, Neeson PJ, Berridge MV, Ritchie DS. The level of glycolytic metabolism in acute myeloid leukemia blasts at diagnosis is prognostic for clinical outcome. J Leukoc Biol. 2011;89(1):51–5. https://doi.org/10.1189/jlb.0710417.CrossRefPubMed

15.

Wang JH, Chen WL, Li JM, Wu SF, Chen TL, Zhu YM, et al. Prognostic significance of 2-hydroxyglutarate levels in acute myeloid leukemia in China. Proc Natl Acad Sci USA. 2013;110(42):17017–22. https://doi.org/10.1073/pnas.1315558110.CrossRefPubMedPubMedCentral

16.

Wang Y, Zhang L, Chen WL, Wang JH, Li N, Li JM, et al. Rapid diagnosis and prognosis of de novo acute myeloid leukemia by serum metabonomic analysis. J Proteome Res. 2013;12(10):4393–401. https://doi.org/10.1021/pr400403p.CrossRefPubMed

17.

Shafat MS, Gnaneswaran B, Bowles KM, Rushworth SA. The bone marrow microenvironment—home of the leukemic blasts. Blood Rev. 2017;31(5):277–86. https://doi.org/10.1016/j.blre.2017.03.004.CrossRefPubMed

18.

Aa J, Yu L, Sun M, Liu L, Li M, Cao B, et al. Metabolic features of the tumor microenvironment of gastric cancer and the link to the systemic macroenvironment. Metabolomics. 2012;8(1):164–73. https://doi.org/10.1007/s11306-011-0297-0.CrossRef

19.

Bjerrum JT. Metabonomics: analytical techniques and associated chemometrics at a glance. Methods Mol Biol. 2015;1277:1–14. https://doi.org/10.1007/978-1-4939-2377-9_1.CrossRefPubMed

20.

Trygg J, Holmes E, Lundstedt T. Chemometrics in metabonomics. J Proteome Res. 2007;6(2):469–79. https://doi.org/10.1021/pr060594q.CrossRefPubMed

21.

Chong J, Soufan O, Li C, Caraus I, Li S, Bourque G, et al. MetaboAnalyst 4.0: towards more transparent and integrative metabolomics analysis. Nucleic Acids Res. 2018;46(W1):W486–W494494. https://doi.org/10.1093/nar/gky310.CrossRefPubMedPubMedCentral

22.

Son J, Lyssiotis CA, Ying H, Wang X, Hua S, Ligorio M, et al. Glutamine supports pancreatic cancer growth through a KRAS-regulated metabolic pathway. Nature. 2013;496(7443):101–5. https://doi.org/10.1038/nature12040.CrossRefPubMedPubMedCentral

23.

Gao P, Tchernyshyov I, Chang TC, Lee YS, Kita K, Ochi T, et al. c-Myc suppression of miR-23a/b enhances mitochondrial glutaminase expression and glutamine metabolism. Nature. 2009;458(7239):762–5. https://doi.org/10.1038/nature07823.CrossRefPubMedPubMedCentral

24.

Wise DR, Thompson CB. Glutamine addiction: a new therapeutic target in cancer. Trends Biochem Sci. 2010;35(8):427–33. https://doi.org/10.1016/j.tibs.2010.05.003.CrossRefPubMedPubMedCentral

25.

Liu XX, Li XJ, Zhang B, Liang YJ, Zhou CX, Cao DX, et al. MicroRNA-26b is underexpressed in human breast cancer and induces cell apoptosis by targeting SLC7A11. FEBS Lett. 2011;585(9):1363–7. https://doi.org/10.1016/j.febslet.2011.04.018.CrossRefPubMed

26.

Zhao X, Li Y, Wu H. A novel scoring system for acute myeloid leukemia risk assessment based on the expression levels of six genes. Int J Mol Med. 2018;42(3):1495–507. https://doi.org/10.3892/ijmm.2018.3739.CrossRefPubMedPubMedCentral

27.

Frezza C. Cancer metabolism: addicted to serine. Nat Chem Biol. 2016;12(6):389–90. https://doi.org/10.1038/nchembio.2086.CrossRefPubMed

28.

Mattaini KR, Sullivan MR, Vander Heiden MG. The importance of serine metabolism in cancer. J Cell Biol. 2016;214(3):249–57. https://doi.org/10.1083/jcb.201604085.CrossRefPubMedPubMedCentral

29.

Newman AC, Maddocks ODK. Serine and functional metabolites in cancer. Trends Cell Biol. 2017;27(9):645–57. https://doi.org/10.1016/j.tcb.2017.05.001.CrossRefPubMed

30.

Maddocks ODK, Athineos D, Cheung EC, Lee P, Zhang T, van den Broek NJF, et al. Modulating the therapeutic response of tumours to dietary serine and glycine starvation. Nature. 2017;544(7650):372–6. https://doi.org/10.1038/nature22056.CrossRefPubMed

31.

Wojtowicz W, Chachaj A, Olczak A, Zabek A, Piatkowska E, Rybka J, et al. Serum NMR metabolomics to differentiate haematologic malignancies. Oncotarget. 2018;9(36):24414–27. https://doi.org/10.18632/oncotarget.25311.CrossRefPubMedPubMedCentral

32.

Chen WL, Wang JH, Zhao AH, Xu X, Wang YH, Chen TL, et al. A distinct glucose metabolism signature of acute myeloid leukemia with prognostic value. Blood. 2014;124(10):1645–54. https://doi.org/10.1182/blood-2014-02-554204.CrossRefPubMedPubMedCentral

33.

Wang X, Zhao X, Chou J, Yu J, Yang T, Liu L, et al. Taurine, glutamic acid and ethylmalonic acid as important metabolites for detecting human breast cancer based on the targeted metabolomics. Cancer Biomark. 2018;23(2):255–68. https://doi.org/10.3233/cbm-181500.CrossRefPubMed

34.

Dazhi W, Jing D, Chunling R, Mi Z, Zhixuan X. Elevated SLC6A6 expression drives tumorigenesis and affects clinical outcomes in gastric cancer. Biomark Med. 2019;13(2):95–104. https://doi.org/10.2217/bmm-2018-0256.CrossRefPubMed

35.

Stuani L, Riols F, Millard P. Stable isotope labeling highlights enhanced fatty acid and lipid metabolism in human acute myeloid leukemia. Int J Mol Sci. 2018;19(11):3325. https://doi.org/10.3390/ijms19113325.CrossRefPubMedCentral

36.

Hao GW, Chen YS, He DM, Wang HY, Wu GH, Zhang B. Growth of human colon cancer cells in nude mice is delayed by ketogenic diet with or without omega-3 fatty acids and medium-chain triglycerides. Asian Pac J Cancer Prev. 2015;16(5):2061–8.CrossRefPubMed

37.

Li L, Pilo GM, Li X, Cigliano A, Latte G, Che L, et al. Inactivation of fatty acid synthase impairs hepatocarcinogenesis driven by AKT in mice and humans. J Hepatol. 2016;64(2):333–41. https://doi.org/10.1016/j.jhep.2015.10.004.CrossRefPubMed

Title: Metabolomics analysis identifies lysine and taurine as candidate prognostic biomarkers for AML-M2 patients
Authors: Xuan Zhou
Meihong Zheng
Qien Wang
Jiye Aa
Bei Cao
Juan Li
Publication date: 01-06-2020
Publisher: Springer Singapore
Keywords: Acute Myeloid Leukemia
Biomarkers
Published in: International Journal of Hematology / Issue 6/2020
Print ISSN: 0925-5710
Electronic ISSN: 1865-3774
DOI: https://doi.org/10.1007/s12185-020-02836-7

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 6/2020

Nitrosourea, etoposide and cyclophosphamide followed by autologous stem cell transplantation for pediatric lymphoma patients

Comparison of clinical phenotype with genetic and laboratory results in 31 patients with congenital dysfibrinogenemia in northern Slovakia

Health-related quality of life in peripheral blood stem cell donors and bone marrow donors: a prospective study in Japan

Clinical outcomes of persistent colonization with multidrug-resistant Gram-negative rods in adult patients undergoing single cord blood transplantation

Prediction of response to first-line therapy with ITP by flow cytometric analysis of bone marrow lymphocyte phenotypes

Does patient sex play a role in treatment-free remission in chronic myeloid leukemia?

Keynote webinar | Spotlight on antibody–drug conjugates in cancer